NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study

被引：0
|
作者：
Gregorc, V. [1 ]
Ceresoli, G. L. [2 ]
Zucali, P. A. [2 ]
De Braud, F. G. [3 ]
Bajetta, E. [4 ]
Santoro, A. [2 ]
Vigano, M. G. [1 ]
Cappio, F. Caligaris [1 ]
Lambiase, A. [5 ]
Bordignon, C. [5 ]
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Ist Clin Humanitas, Dept Oncol, Milan, Italy
[3] Ist Europeo Oncol, Clin Pharmacol & New Drugs Unit, Milan, Italy
[4] IRCCS Fdn, Ist Nazl Tumori, Dept Oncol, Milan, Italy
[5] MolMed, Clin Dev, Milan, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71724-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 509
页数：1
相关论文
共 50 条
  • [1] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Ceresoli, G. L.
    Zucali, P. A.
    De Braud, F. G.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM)
    De Vincenzo, F.
    Rossoni, G.
    Santoro, A.
    Gregorc, V.
    Zucali, P. A.
    Citterio, G.
    Simonelli, M.
    Petrella, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] PHASE II CLINICAL TRIAL OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), AS SECOND-LINE THERAPY IN MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Ceresoli, G. L.
    Gregorc, V.
    Zucali, P. A.
    Noberasco, C.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 119 - 119
  • [4] NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
    Gregorc, V.
    Zucali, P.
    Ceresoli, G. L.
    Noberasco, C.
    Bajetta, E.
    Santoro, A.
    Vigano, M. G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [5] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    De Braud, F. G.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    Gregorc, V.
    Rimassa, L.
    De Braud, F. G.
    Rossoni, G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 395
  • [7] NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM)
    Rossoni, Gilda
    Gregorc, Vanesa
    Vigano, Maria Grazia
    Bulotta, Alessandra
    Ghio, Domenico
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM)
    Gregorc, V.
    Gaafar, R.
    Favaretto, A.
    Grossi, F.
    Jassem, J.
    Polychronis, A.
    Bidoli, P.
    Tiseo, M.
    O'Brien, M.
    Shah, R.
    Taylor, P.
    Novello, S.
    Muzio, A.
    Bearz, A.
    Badurak, P.
    Greillier, L.
    Fontana, F.
    Colombi, S.
    Lambiase, A.
    Bordignon, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S634 - S634
  • [9] NGR-hTNF Vascular Targeting Agent Oncolytic
    Vasitiou, S.
    Suria, R.
    DRUGS OF THE FUTURE, 2011, 36 (04) : 281 - 285
  • [10] Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours
    Citterio, G.
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Noberasco, C.
    Boselli, S.
    Giovannini, M.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 129 - 129
12345